Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

AstraZeneca Inaugurates Global Process R&D lab in Bangalore

Published: Thursday, March 22, 2007
Last Updated: Thursday, March 22, 2007
Bookmark and Share
According to AstraZenec, the facility will strengthen the global PR&D programmes as well as provide support to the existing Drug Discovery programme at Bangalore.

AstraZeneca has inaugurated a new Process and Development (PR&D) laboratory next to its R&D centre in Bangalore, India.

Mr. David Brennan, Chief Executive Officer AstraZeneca, along with Guests of Honour, Mr P B Mahishi, Chief Secretary, Govt. of Karnataka, & Mr. Narayana Murthy, Chairman & Chief Mentor, Infosys Technologies, officially opened the laboratory at the company’s Hebbal campus in Bangalore.

The PR&D facility, built at a cost of $15 million, covers 8,000 square metres on a 14,200 square metre plot and can accommodate up to 75 process scientists, supported by office and engineering staff. This is AstraZeneca’s fourth PR&D facility and the only one outside of Europe. The company has two PR&D facilities in the UK and one in Sweden.

Mr. Brennan said, “I am delighted and privileged to inaugurate this PR&D facility to further demonstrate AstraZeneca’s commitment to our operations in India and to our team of researchers and scientists here who are dedicated to the discovery of novel therapies for developing world diseases. Facilities of this kind will leverage India’s strengths in process chemistry”.

This facility will strengthen the existing global PR&D programmes as well as provide support to the existing Drug Discovery programme at Bangalore, engaged in finding a cure for tuberculosis (TB), a disease prevalent in the developing world and making a re-appearance in developed countries.

Dr. Sudhir Nambiar, Director, PR&D, AstraZeneca India, said: “This is an exciting challenge for the skilled and dedicated Indian chemists who have already proved themselves in the generic area. We plan to recruit additional scientists from the organic, analytical and process engineering disciplines from universities directly or with varying levels of local/overseas industrial experience”.

A focus area of this facility will be New Chemical Entities (NCEs). The PR&D scientists typically work with compounds created by medicinal chemists to ensure that they are safe and efficient for the manufacturing related stages of drug development as well as toxicological studies & clinical trials. The co-location at Bangalore of Discovery and PR&D scientists will help AstraZeneca to maximize scientific interactions and enable shared use of the PR&D infrastructure.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca and MAP Collaborate for Development and Commercialization of Unit Dose Budesonide
Unit Dose Budesonide is being developed as a potential treatment for pediatric asthma and is currently in Phase III clinical development.
Monday, December 22, 2008
AstraZeneca Announces Partnership with Singapore Institutions to Develop Anti-Cancer Compounds
The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients.
Tuesday, August 19, 2008
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
Wednesday, July 02, 2008
AstraZeneca Enhances Clinical Research Capabilities in China with First Clinical Pharmacology Unit
The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients.
Wednesday, September 05, 2007
Integration of the Hamilton Microlab Star within HtL at AstraZeneca R&D Charnwood
The use of the flexible and modular Microlab® Star enables AstraZeneca to use one instrument for diverse applications ranging from compound dilution to assay construction.
Wednesday, June 06, 2007
Scientific News
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Pharmacy on Demand
New, portable system can be configured to produce different drugs.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Countless New, Cleaner Uses of Methane
Chemists have demonstrated the potential to use methane as a versatile chemical building block with which to make more complex molecules.
New Way to Control Chemical Reactions
Scientists have harnessed static electricity to control chemical reactions for the first time, in a breakthrough that could bring cleaner industry and cheaper nanotechnology.
Tiny 'Flasks' Speed Up Chemical Reactions
Self-assembling nanosphere clusters may improve everything from drug synthesis to drug delivery.
The Manufacturing Challenges of Nanotechnology
Head of NanoManufacturing at the Department of Engineering’s Institute for Manufacturing (IfM) Dr Michaël de Volder explains why manufacturing carbon nanotubes is so difficult – and so important.
New Material Lays Waste to Mercury Pollution
A brand new, dirt cheap, non-toxic polymer that literally sucks mercury out of water and soil is set to become a game changer in the battle against one of the world’s most reviled pollutants.
Shocking New Way to Get the Salt Out
MIT team invents efficient shockwave-based process for desalination of water.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos